August 2, 2018
Daiichi Sankyo said on August 1 that the FDA designated its FLT3 inhibitor quizartinib as a Breakthrough Therapy for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). The designation is based on a global PIII trial,...read more